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Abstract
Introduction
Liver enzyme levels and total serum bilirubin are under genetic control and in recent years
genome-wide population-based association studies have identified different susceptibility
loci for these traits. We conducted a genome-wide association study in European ancestry
participants from the Electronic Medical Records and Genomics (eMERGE) Network data-
set of patient medical records with available genotyping data in order to identify genetic con-
tributors to variability in serum bilirubin levels and other liver function tests and to compare
the effects between adult and pediatric populations.
Methods
The process of whole genome imputation of eMERGE samples with standard quality control
measures have been described previously. After removing missing data and outliers based
on principal components (PC) analyses, 3294 samples from European ancestry were used
for the GWAS study. The association between each single nucleotide polymorphism (SNP)
and total serum bilirubin and other liver function tests was tested using linear regression,
adjusting for age, gender, site, platform and ancestry principal components (PC).
Results
Consistent with previous results, a strong association signal has been detected for UGT1A
gene cluster (best SNP rs887829, beta = 0.15, p = 1.30x10-118) for total serum bilirubin
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level. Indeed, in this region more than 176 SNPs (or indels) had p<10−8 spanning 150Kb on
the long arm of chromosome 2q37.1. In addition, we found a similar level of magnitude in a
pediatric group (p = 8.26x10-47, beta = 0.17). Further imputation using sequencing data as a
reference panel revealed association of other markers including known TA7 repeat indels
(rs8175347) (p = 9.78x10-117) and rs111741722 (p = 5.41x10-119) which were in proxy (r2 =
0.99) with rs887829. Among rare variants, two Asian subjects homozygous for coding SNP
rs4148323 (G71R) were identified. Additional known effects for total serum bilirubin were
also confirmed including organic anion transporters SLCO1B1-SLCO1B3, TDRP and
ZMYND8 at FDR<0.05 with no gene-gene interaction effects. Phenome-wide association
studies (PheWAS) suggest a protective effect of TA7 repeat against cerebrovascular dis-
ease in an adult cohort (OR = 0.75, p = 0.0008). Among other liver function tests, we also
confirmed the previous effect of the ABO blood group locus for variation in serum alkaline
phosphatase (rs579459, p = 9.44x10-15).
Conclusions
Taken together, our data present interesting findings with strong confirmation of previous
effects by simply using the eMERGE electronic health record phenotyping. In addition, our
findings indicate that similar to the adult population, the UGT1A1 is the main locus responsi-
ble for normal variation of serum bilirubin in pediatric populations.
Introduction
Bilirubin is the ultimate product of catabolism of heme with complex interplay of different
enzymes. Levels of serum bilirubin are significantly elevated in a number of diseases associated
with jaundice and hemolytic blood disorders. Bilirubin levels have a large variability in normal
population and bilirubin concentration is under strong genetic regulation with a heritability
estimate of roughly 0.50 [1]. In particular, polymorphism TATA box promoter motif in the
UGT1A1 gene promoter (UGT1A128, rs8175347) is associated with UGT1A1 expression [2];
the mean bilirubin levels of TA7 homozygotes are approximately double those of TA6 homo-
zygotes [3–5].
This homozygosity predisposes individuals not only to Gilbert syndrome which is a benign
form of episodic jaundice [2] but also to hyperbilirubinemia induced by several drugs, such as
Indinavir, an HIV protease inhibitor, that competitively inhibits UGT enzymatic activity [6].
In addition, TA7 homozygote individuals are also susceptible to severe neutropenia following
the administration of Irinotecan, an anti-cancer drug mainly used in metastatic colorectal can-
cer patients [7]. In this instance, there is a decrease in the inactivation process of the active
metabolite SN-38 by glucuronidation to SN-38 glucuronide (SN-38G) [7]. Apart from classical
TA repeat insertion, recent data have also shown that other common variants can contribute to
mild hyperbilirubinemia in an additive manner with TA repeat, in particular rs4124874 and a
coding SNP in UGT1A1 rs4148323 (G71R), with an influence on expression levels of UGT1A1
[8,9]. However, their minor allele frequencies are variable across populations and therefore
lead to varying effects of Irinotecan application depending on ethnicity [10,11]. For example,
rs4148323 (G71R) which is almost non-polymorphic in European and African population has
a minor allele frequency of about 20% in Asians while TA7 repeat is less frequent in this popu-
lation (~10%) [12].
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Homozygosity for rare pathogenic coding variants on the other hand are responsible for
severe deficiency of enzymatic activity that range from lethal hyperbilirubinemia (Crigler-Naj-
jar type 1) with zero enzyme activity to Crigler-Najjar type 2 (CN-2) with very low enzyme
activity [13, 14]. These pathogenic variants are extremely rare in the general population.
Founded in 2007, the eMERGE Network is a consortium of multiple adult and pediatric
institutions using biorepositories linked to electronic medical record (EMR) systems for large-
scale genomic research [15]. As part of this network, we conducted this study in order to test
the validity of phenotypic data derived from EMR and the capability of this network for genetic
research.
Genome-wide association studies (GWAS) for total serum bilirubin or other liver function
tests previously have been reported in different ancestries of well characterized adult popula-
tions [16–24]; however, the genetic contribution in a pediatrics population has not been specif-
ically evaluated. There is a tendency toward more extreme phenotypes in pediatrics and some
genomic effects may be age dependent or stronger in earlier stage of development than later
on. In addition, understanding genomic loci that operate in pediatric population are especially
important for a better health care since there is an opportunity for early preventive measures as
well as long term implementation of a treatment plan in order to avoid further hepatotoxicity
and hyperbilirubinemia. Finally the joint effect model of pediatric and adults will provide a bet-
ter estimate of percentage of variance explained. In this study, we investigate whether suscepti-
bility loci identified by GWAS in adults are associated in children and adolescents. For this
purpose, we conducted quantitative GWAS analyses for liver function tests in a primarily Euro-
pean-derived population and compared the observed size effects between pediatric and adult
participants from the eMERGE Network.
Materials and Methods
Ethics statement
The eMERGE Network is a collaboration of institutions with biobanks linked to EMRs. The
detail of recruitment and biological sample collection of eMERGE cohorts has been described
previously [15]. De-identified samples linked to EMR were supplied from multiple investiga-
tors from different institutions with approval from their respective institutional review boards
(IRBs) including Cincinnati Children’s Hospital Medical Center, Boston Children’s Hospital,
Geisinger Health System, Group Health Research Institute and Marshfield Clinic [15]. All
study participants provided written consent prior to study enrollment as part of the DNA bio-
bank in each site. Written informed consent was obtained from the next of kin, caretakers, or
guardians on behalf of the minors/children enrolled in the study and have been approved by
the IRB.
Study participants
De-identified samples from five different eMERGE sites were evaluated (Table 1). Children
and teens, aged through 19 years old composed the pediatric population. For GWAS and Phe-
WAS analyses only those self-reported to have European ancestry and with normal ranges of
liver function tests were selected (Table 1), (details described under “Phenotyping”).
Genotyping and imputation
High throughput SNP genotyping was carried out previously in each respective facility as
shown in Table 1. Quality control (QC) of the data was performed before imputation. In each
genotyped cohort, standard quality control criteria were met and single nucleotide
Genome-Wide Association Study of Liver Function Tests Using eMERGE
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polymorphisms (SNPs) were removed if (a)>5% of the genotyping data was missing, (b) out
of Hardy-Weinberg equilibrium (HWE, p< 0.0001) in controls, or a minor allele frequency
(MAF)<1%. Samples with call rates<98% were excluded. Recently all eMERGE cohorts have
undergone whole genome imputation as described [25]. The imputation pipeline includes
SHAPEIT2/IMPUTE2 program and the publicly available 1000-Genomes Project as the refer-
ence haplotype panel composed of 1092 samples (release version 2 fromMarch 2012 of the
1000 Genomes Project Phase I, ftp://ftp-trace.ncbi.nih.gov/1000genomes/ftp/release/
20110521) [26].
The basic quality controls for eMERGE imputed data provided to us included a threshold of
0.90 for the genotype posterior probability and info score> 0.7 [25]. Info score is the informa-
tion metric that IMPUTE2 reports [26]. This metric typically takes values between 0 and 1,
where values near 1 indicate that a SNP has been imputed with high certainty. This is often
used to remove poorly imputed SNPs. Principal component analysis (PCA) was performed to
identify outliers and hidden population structure using EIGENSTRAT [27]. The first three
principal components explained most of the variance and were retained and used as covariates
during the association analysis in order to adjust for population stratification. In addition,
UGT1A1 whole exome sequencing data were available to use from the eMERGE-PGx project
(a Network collaboration with Pharmacogenomics Research Network (PGRN)) dataset derived
from 5163 independent samples from different ancestries [28]. To increase the resolution of
the association signal at UGT1A1, this collection was then phased and used as a reference
panel for secondary imputation using the SHAPEIT2/IMPUTE2 pipeline described above [26].
Phenotyping
Levels of serum bilirubin are significantly elevated in a number of diseases. Therefore, we first
excluded conditions that either cause overproduction (e.g hemolytic diseases) or decreased in
excretion of bilirubin (e.g hepatobiliary diseases). These include ICD-9 codes of 570 to 579.99
with 101 distinct diseases (Chronic liver disease and cirrhosis, Alcoholic fatty liver, drug
induced liver disease, gallbladder disease), diagnostic codes of 280 to 289.99 for blood related
diseases with 133 categories including hemolytic anemia or Sickle cell disease as well as blood
related malignancy with ICD-9 codes of 200 to 209.99 with 391 categories. We also excluded
Table 1. The demographic distribution of EMR-linked eMERGE cohorts.
Cohorts eMERGE-Sites #Europeans M/F Platforms Mean age (±SD)
Pediatrics BCH 148 92/56 Affymetrix-Axiom 13.30 (5.47)
CCHMC 419 272/147 Illumina-610
217 128/89 Illumina-Omni-1
184 112/72 Illumina-Omni-5
99 12/87 Affymetrix-6
CCHMC-Total 919 524/395 11.52 (5.35)
Adults Marshﬁeld 728 339/389 Illumina660W
50 7/43 Affymetrix-6
Marshﬁeld-Total 778 346/432 64.9 (11.46)
Geisinger 691 459/232 Illumina-Omni-Express 70.7 (13.81)
GroupHealth 657 288/369 Illumina660W
101 63/38 Illumina-Omni-Express
GroupHealth-Total 758 351/407 67.4 (14.92)
Total 3294 1772/1522
doi:10.1371/journal.pone.0138677.t001
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those undergoing chemotherapy or transplant. The same exclusion rules were applied to other
liver function enzymes.
Since transient physiologic hyperbilirubinemia is common in the neonatal period, we also
excluded children less than one year old. Due to the nature of electronic medical records and
since ICD-9 codes, per se, may not be specific and due to underdiagnosed conditions or errors,
an additional filtration step was applied in which we excluded samples that still had any out of
normal range values (>2 mg/dl) for total serum bilirubin [29,30]. After these filtration steps,
the latest lab measures were used for analyses. For other liver enzymes (ALT, ASP, GGT and
ALP) and because of wider normal data ranges, natural log-transformations were generated
and used for Linear-regression analyses to preserve normal distribution.
A phenome-wide association analysis (PheWAS) was performed in which presence or
absence of each PheWAS code that mapped from translated ICD-9 codes were considered as a
binary phenotype as described previously [31]. These PheWAS codes were used to define case
and control group. Control groups for Crohn’s Disease (CD), for instance, excluded CD, ulcer-
ative colitis and several other related gastrointestinal complaints. The current PheWAS map is
available at (http://phewascatalog.org).
Genome-wide Association Statistics
After performing quality control measures mentioned above, we tested 3,301,391 autosomal
SNPs for quantitative association study. Linear-regression analyses assuming an additive
genetic model was used on latest total serum bilirubin, ALT, ALP, and AST and GGT using
PLINK software package and adjusted by age, sex, principal components, sites and genotyping
platforms [32]. In addition, previously known variants associated with serum bilirubin level
from the NHGRI catalog were selected as a priori list of 9 autosomal candidate genes and eval-
uated separately in order to confirm these effects, in which false discovery rate (FDR) methods
were used to correct for multiple testing using the Benjamini–Hochberg procedure imple-
mented in PLINK [32]. PLINK was also used for conditional analyses and pairwise SNP-SNP
interactions (epistasis) [32]. The ‘‘epistasis” option in PLINK provides a logistic regression test
for interaction that assumes an allelic model for interactions and their principal effects in
which PLINK makes a model based on allele dosage for each SNP [32]. To graphically display
results, LocusZoom and Golden Helix programs were used [33, Golden Helix GenomeB-
rowse1 visualization tool (Version 8.3.0). Bozeman, MT: Golden Helix, Inc. Available from
http://www.goldenhelix.com).
Results
Characteristics of the study participants are presented in Table 1. After exclusions of series of
disease conditions described in the Methods, the latest serum bilirubin level and other liver
function tests were used for analyses. As shown in Table 1, the mean ± SD age was 67.7±13.40
for adult participants and 12.4±5.43 for pediatrics participants. The mean ± SD of total biliru-
bin level was 0.56±0.28. All studies showed significantly higher bilirubin levels in males than
females, as expected. The mean of total serum bilirubin in males was 0.59±0.31 mg/dl and 0.52
±0.26 mg/dl in females. Similarly, it was higher in adults than children (mean± SD of 0.61
±0.28 in adults, 0.44 ±0.28 in children). Therefore for all analyses, age- and sex-adjusted analy-
ses (covariates described in Materials and Methods) were conducted.
Consistent with previous reports, we identified strong genetic signals at UGT1A1 locus
at 2q37. Fig 1 shows the Manhattan plot of this GWAS effect. The overall low inflation rate
of (λ = 1.004) was observed. Indeed, the best SNP, rs887829, produced p = 1.30x10-118,
beta = 0.15. This is equal to an OR = 6.35 when we consider 10% of tail distribution as cases
Genome-Wide Association Study of Liver Function Tests Using eMERGE
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and controls (Table 2). As shown in Table 2, the effect was also strong in the pediatric-only
cohort with 1067 participants (p = 8.26x10-47, beta = 0.18).
Next, in order to increase the resolution of this association signal we imputed additional
variants using the PGRN sequencing dataset as a reference panel [28]. As a result additional
association signals for a number of imputed variants were detected that pass the quality thresh-
old (info score>0.7). In particular, the TA7 indel repeat (rs8175347) that was in linkage dis-
equilibrium with the top marker (rs887829, r2 = 0.99) was imputed and with similar
magnitude of effect (p = 9.78x10-117, beta = 0.15). Another imputed intronic marker,
rs111741722, produced the highest effect in this study (p = 5.41x10-119, beta = 0.15). Fig 2
shows the haplotypic LD structure of the TA repeat with nearby markers that all generate simi-
lar magnitude of results. Indeed, in this region more than 176 SNPs (or indels) had p<10–8
spanning 150Kb on the long arm of chromosome 2q37.1 (Fig 3). As shown in Fig 2, SNP
rs4124874, which also influences gene expression [9] was an incomplete proxy for TA repeat
Fig 1. (A and B) Manhattan plot and Q–Q plot of genome-wide markers for total serum bilirubin in 3294
European samples respectively.
doi:10.1371/journal.pone.0138677.g001
Table 2. Quantitative and case-control association result of top SNPs in UGT1A1 for total serum bilirubin levels in pediatric and adult subgroups.
Sample size CHR SNP Position* Beta p value†
Pediatrics 1067 2 rs887829-T 234668570 0.177 8.26E-47
Adult 2227 2 rs887829-T 234668570 0.147 2.00E-63
Total 3294 2 rs887829-T 234668570 0.157 1.30E-118
tail-pheno Case/Control OR p value‡
Decile 354/370 2 rs887829-T 234668570 6.347 (5.02–8.01) 8.76E-59
*Map Position: NCBI build 37.
†linear regression association test.
‡Chi-square test.
doi:10.1371/journal.pone.0138677.t002
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(r2 = 0.60 and produced p = 6.66x10-75, beta = 0.12). After conditional analysis controlling for
this marker, the TA repeat locus still remained significant (p = 3.58x10-42); on the other hand
conditioning on the TA repeat diminished significantly all association signal for rs4124874,
p = 0.90 suggesting that the TA repeat mainly explains global variations in this region. As
shown in Fig 2, TA repeat was in perfect LD with 5 SNP markers (rs887829, rs111741722,
rs6742078, rs4148324, rs4148325) spanning less than 10KB, therefore, further conditional
analyses were not possible.
Other effects
Apart from UGT1A1 effect, no other effects reach a genome significance level (P<10–8) in our
cohorts (Fig 1A). There is one other locus at 12p12 (SLCO1B1-SLCO1B3) that is consistently
Fig 2. The LD structure betweenmarkers in peak association signals. r2 = correlation coefficient as a
measure of linkage disequilibrium.
doi:10.1371/journal.pone.0138677.g002
Fig 3. A schematic representation of association map at UGT1A region for total serum bilirubin. The
TA repeat location is shown with vertical line.
doi:10.1371/journal.pone.0138677.g003
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reported to be associated with total serum bilirubin at less magnitude [16,17]. In addition, sev-
eral other genes suggestively have been reported to be associated. We, therefore, more thor-
oughly evaluated these variants and obtained 9 distinct lead SNPs from the NHGRI catalog
and confirmed several previously reported associations for bilirubin at the level of FDR<0.05.
These include SLCO1B1-SLCO1B3, TDRP and ZMYND8 (Table 3). SLCO1B1 is an organic
anion transporter (OATP1B1) important for uptake of bilirubin in liver. The nonsynonymous
SNP, rs4149056 V174A, which alters uptake activity of this transporter produced p = 0.0004,
beta = 0.03 in our combined cohorts (Table 3). In this region SNPs located at SLCO1B3 was
also associated including rs10841661 (Table 3). There was a 350Kb distance between these two
family members of B1 and B3 with r2 = 0.002. Therefore, conditional analysis controlling for
rs4149056 still shows association effects at rs10841661 (p = 0.0008) suggesting an independent
effect in SLCO1B3.
We next tested for any effect of the UGT1A1 gene on the association of bilirubin levels with
these genes and SNP rs887829, the top marker on the UGT1A1 locus in the model, was used
for conditional analyses. As shown in Table 2, no association disappeared after controlling for
rs887829, suggesting that part of the variability of total serum bilirubin can be explained by
these other genes. Furthermore, although no significant gene-gene interaction was observed,
some association improved (Table 3).
Rare effects
In the UGT1A1 gene, there are more than 50 known stop codon, gain of function or frame shift
mutations reported in families with CN-type 1 or 2 [34]. These mutations are extremely rare
and homozygosity is link to autosomal recessive early lethality especially in CN type I. In
PGRN sequencing data we identified 16 of these variants in 44 participants but all were carriers
(heterozygous); Serum total bilirubin were available for 9 of them that all were within normal
range consistent with a recessive effect. No homozygote recessive or compound heterozygote
participants were detected.
As mentioned above the SNP rs4148323 (G71R) mutation is more common in the Asian
population. This variant is associated with a milder form of hyperbilirubinemia and Gilbert’s
syndrome. PGRN sequencing data revealed two Asian participants that were homozygous for
coding SNP rs4148323 (G71R). The means of total serum bilirubin for these participants were
1.52 (95% CI = 1.032–2.018) and 0.85 (95%CI 0.68–1.0) respectively. They have not been diag-
nosed clinically with jaundice according to EMR, nor did they have any risk alleles in TA
repeat, rs4124874 or any other detected rare variants.
Table 3. Other effects associated with total serum bilirubin at FDR<0.05.
CHR Gene SNP BP Minor
allele*
BETA P
value
P value- Adjusted for
rs887829
P value- Interaction with
rs887829
REF
8 TDRP rs17665859 445601 C 0.037 0.003 0.009 0.28 17
12 SLCO1B3 rs10841661 20984832 T 0.025 0.0003 0.0006 0.24 20
12 SLCO1B3 rs17680137 21015906 G 0.029 0.001 0.0013 0.75 20
12 SLCO1B1 rs4149056 21331549 C 0.032 0.0004 0.00009 0.21 16
20 ZMYND8 rs7262634 45834279 C 0.042 0.005 0.0192 0.2 24
Conditional P values adjusted for lead SNP in UGT1A1 (rs887829) as well as pairwise SNPxSNP interactions with (rs887829) are shown.
*All effects are for minor alleles.
doi:10.1371/journal.pone.0138677.t003
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Other Liver function test
Except for serum total alkaline phosphatase, no other liver enzymes produced a genome wide
significant effect (P<1x10-8). The effect of the ABO blood group locus and total alkaline phos-
phatase that has been replicated in different studies was confirmed in our study (best p1x10-
15 for SNP rs600038, Table 4, Fig 4A). The effect was consistent across pediatric and adult
cohorts. ABO blood type is known to be correlated with serum alkaline phosphatase, therefore
we next identified perfect surrogate SNPs tagging ABO alleles in our dataset which include:
rs8176704 for the A allele, rs505922 (or rs612169) for the O allele and rs8176746 (or
rs8176672) for the B allele [35,36]. As shown in Fig 4B, after controlling for all three ABO SNP
determinants, the association signal dramatically reduced for the lead SNP rs600038 with p-
conditional = 0.02, consistent with previous studies. Of note, the linkage disequilibrium
between lead SNP rs600038 and three ABO SNP determinants (rs505922 and rs8176746,
rs8176704) were r2 = 0.39, 0.03 and 0.01 respectively.
Table 4.
Enzyme Gene CHR SNP BP Minor allele BETA P value REF
ALP ABO 9 rs651007 136153875 T -0.034 1.06E-14 22,23
ABO 9 rs600038 136151806 C -0.034 8.608e-15 22,23
ABO 9 rs579459 136154168 C -0.034 9.436e-15 22,23
doi:10.1371/journal.pone.0138677.t004
Fig 4. (A) The association signal between total serumALP and the ABO blood locus. (B): The
association of lead SNPs at the ABO locus with serumALP and their relation with ABO tag SNPs
(rs8176746, rs8176704, rs505922); A significant drop in association effect in lead SNPs after
controlling for ABO-tag SNPs are shown (red and black dots represent before and after conditional
analyses respectively).
doi:10.1371/journal.pone.0138677.g004
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PheWAS approach
To explore pleiotropy of the TA-repeat in UGT1A1 for other clinical diagnoses, we performed
a PheWAS study in adult and pediatric cohorts separately using available ICD-9 codes as previ-
ously described [31]. As expected, since we excluded all participants with hyperbilirubinemia
and related conditions, we did not find any associations for these conditions. There were 377
distinct diagnostic codes for adults with minimum of 100 participants in each category. After
correcting for multiple comparisons, no results remained significant. The best overall effect
was a trend toward associations with cerebrovascular disease and ischemic stroke in adult-only
cohorts adjusting for age, gender, site, platforms and PCs (unadjusted p = 0.0008, adjusted
p = 0.056, OR = 0.75, 95%CI 0.63–0.88). There were 464 cases with this diagnosis and 1433
controls. Of note this was a protective effect for the TA7 repeat. In addition, results for other
atherosclerosis-related conditions such as ischemic cardiovascular disease were in the same
direction but only suggestive (data not shown). The number of samples for these conditions
were small in pediatrics cohorts (<10).
Discussion
In this GWAS analysis from five eMERGE sites we confirmed the substantial contribution of
UGT1A1 on human serum bilirubin levels and a number of other transporter genes, including
SLCO1B1 and B3 that influence variation in bilirubin levels. This is the largest GWAS study for
serum bilirubin in a pediatric cohort. We found that this effect is strong in pediatric as well as
adult populations (Table 2). Further imputation using PGRN sequencing data revealed that the
TA indel repeat (UGT1A128, rs8175347) is in strong LD with 5 additional SNPs (r2>0.98)
and mainly responsible for the GWAS signal at this location. Indeed, this locus by itself
explained 14% of total variations of serum bilirubin in our cohorts comparable with previous
studies [16]. In comparison only 0.2% of total variation of serum bilirubin can be explained by
rs4149056 SNP in SLCO1B1 in our cohort. Similar to previous studies, we did not detect a sig-
nificant gene gene interaction between SLCO1B1/B3 and UGT1A1 (p = 0.21, Table 2) [16]. We
confirmed a number of other effects as shown in Table 3 including TDRP and ZMYND8. We
had 90% power to detect such association in our studies (average MAF = 0.10, beta 0.03–0.05,
OR = 1.1–1.2).
We applied a successful strategy using electronic medical records to identify individuals
with normal variations in serum bilirubin and other liver function tests by excluding more
than 300 blood and liver-related diseases and conditions (see method). Electronic health rec-
ords have enormous phenotypic heterogeneity. There are many reasons that a patient may
have hyperbilirubinemia that range from a simple viral hepatitis to hemolytic crises due to
medications. Including serum bilirubin for these non-genetic conditions may produce noise
and skew the normal distribution of the quantitative phenotype under study. Obviously addi-
tional studies are necessary to address any disease specific condition. Similarly we applied strin-
gent quality criteria and thresholds for genotyping data and adjusted all results by age, sex, site
of study, platform and principal components. We evaluated the eMERGE PGRN dataset for
rare variants at UGT1A1 and as a result we identified two Asian participants with homozygous
for the rs4148323 minor allele resulting in a (p.Gly71Arg) coding change. Interestingly they
did not have additional risk alleles in the TA repeat or rs4124874 variants suggesting an inde-
pendent effect for (p.Gly71Arg). One of these participants shows a subclinical hyperbilirubine-
mia (latest total bilirubin = 2.1 mg/dl) possibly associated with the effect of this missense
variant [37]. As mentioned above, this variant is rare in other ancestries. Other available liver
function tests were normal in these two participants. In addition, we identified 44 heterozygote
(or carrier) participants with other potential deleterious mutations such as (rs34993780, p.
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Tyr486Asp). Since homozygous variants are extremely rare in population (1:1000000) with
severe early hyperbilirubinema (CN typ1 or 2), we did not expect to find these homozygotes in
our population panel cohorts. Interestingly no compound heterozygote was detected.
Among other liver function tests, we confirmed the effect of the ABO locus on serum alka-
line phosphatase. This effect has been consistently replicated in other studies [22,23]. Approxi-
mately 90% of serum alkaline phosphatase (ALP) originates from liver, bone and kidney, while
10% from intestine and 1% from placenta [38]. Most of the intestinal ALP is attached to ABO
antigens on the surface of erythrocytes by a glycosyl-phosphatidylinositol anchor, however,
with different binding capacity depending on different blood groups. Erythrocytes of blood
type A bind to almost all intestinal ALP, while erythrocytes of blood type B/O bind to a much
lesser degree. This results in an increase of intestinal ALP in serum of individuals with blood
type B/O [39]. The observation that association between rs600038 and serum ALP dramatically
reduced after adjusting for ABO-related variants support this physiologic process; although a
residual effect exists (p = 0.02, Fig 4B) that may indicate other regulatory roles of this locus for
serum alkaline phosphatase or underlying confounding effects since the ABO locus is associ-
ated with a variety of metabolic related phenotypes including serum levels of intercellular adhe-
sion molecule-1 (ICAM-1), E-selectin, and P-selectin that participate in inflammatory
processes by promoting adhesion of leukocytes to vascular wall endothelium, effects on low-
density lipoprotein and total serum cholesterol levels as well as coronary artery disease and
stroke [35,40,41].
The major strengths of our study include careful quality control and minimal population
stratification. Electronic medical records, however, have several study limitations including
human errors in extraction of lab measurements or errors in billing code and clinical diagnosis.
In addition the population under study may have wide spectrum of different diseases and
therefore cannot represent a random sample from the normal general population. We have
controlled all relevant medical diagnoses in the analyses to avoid potential sampling bias. The
associations with serum bilirubin levels and UGT1A1 were in fact highly consistent with previ-
ous publications that often recruit well-characterized participants.
Total serum bilirubin is associated with several clinical outcomes, including cardiovascular
disease, diabetes and drug metabolism that warrant additional study. In fact, bilirubin is a
potent antioxidant and higher levels of serum bilirubin may offer a therapeutic advantage in
oxidative stress-mediated conditions [42]. In this context, we detected a suggestive protective
effect of TA7 repeat against chronic cerebrovascular disease that point to this direction
(OR = 0.75). Our adult cohort, consist of elderly participants with the mean age of 67.7 (95%
CI 63.00–72.33) that could well-represent a long term sequela of bilirubin on vascular system.
Obviously excluding potential liver disease patients in this study was a key step to clarify the
inverse associations between bilirubin and stroke as discussed in other published works [43].
Finally, susceptibility to severe neutropenia following the administration of Irinotecan in TA7
homozygotes with colon cancer is particularly interesting and this data will be used for future
pharmacogenetic studies across the eMERGE network.
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